Expert Oncology Panel Discusses the Melanoma Development Pipeline in New BOLT / MedPredict Report

In February 2013 BOLT International / MedPredict’s Melanoma Advisory Board discussed how new data and clinical findings on immunologies and targeted therapies are changing both clinical practice and trial protocols.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

www.boltinternational.com

The melanoma clinical data has matured faster than drugs can get through the registration process

Scottsdale, AZ (PRWEB) April 02, 2013

BOLT International / MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Melanoma Thought Leader Panel #34 2013-03,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for treatments in this disease area.

“In this report, our panel debates the impact of recent clinical data related to targeted therapeutics, immunotherapy and chemotherapy. They talk about the challenge they face sequencing new agents - particularly where the melanoma clinical data has matured faster than drugs can get through the registration process,” according to Jeff Berk, the report’s lead author. “Furthermore, upcoming approvals and changes in standard practice will have an immediate impact on a number of ongoing clinical trials.”

Some of the topics discussed in this report include:

➢    Sequencing immunotherapy (ipilimumab, nivolumab, MK-3475, PD-1) and targeted therapy (BRAF; dabrafenib, vemurafenib, LGX-818), (MEK; trametinib, GDC-0973, MEK-162, pimacertib), (PI3K/AKT; SAR245408, BKM-120, GSK2110183)
➢    Next generation immunotherapy approaches (CAR, chimeric antigen receptor; TIL, tumor infiltrating lymphocytes; MICA; other ways to activate T-cells)
➢    Optimal product profiles for new targeted and immunotherapies: binding affinities, activity in brain metastases
➢    BRAF-wt / NRAS mutations
➢    Other topics: cMET, VEGF, FGF (lenvatinib), c-KIT, adjuvant therapy, chemotherapy (Abraxane)

Transcripts of six qualitative interviews with global melanoma thought leaders are included in the report.

Companies discussed in this report: Amgen, Amplimmune, ArQule, AstraZenenca, AvidBiotics, Bayer-Schering, BioMed Valley, Bristol-Myers Squibb, Celgene, CureTech, Daiichi-Sankyo, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Kite, Merck, Novartis, Onyx, Pfizer, Prometheus, Regeneron, Roche/Genentech, Sanofi-Aventis, Takeda

The full report may be purchased by contacting BOLT International.

About BOLT International
Since 1996 BOLT (http://www.boltinternational.com) has provided proprietary consulting services to many of the largest (and smallest) names in Pharma.

About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity. We also provide these reports pro-bono to qualified patients and their physicians.

For more information contact:
Jeff Berk
BOLT International / MedPredict
+1.480.551.7231

###


Contact